Abstract
Recombinant human soluble thrombomodulin (rTM) has been used for treatment of disseminated intravascular coagulation (DIC) since 2010 in our institution. This study was performed in order to investigate the effect of rTM on dose of transfusion and blood products and the change of coagulation parameters in the patients with DIC. We retrospectively compared non-rTM group (27 patients treated with synthetic protease inhibitors in ICU from January to December 2009) and rTM group (34 patients treated with rTM from January 2010 to March 2012). The dose of platelet concentrates (PC), and fresh-frozen plasma (FFP) were significantly lower in rTM group (P=0.05, P=0.04, respectively). rTM administration for DIC might lead to reducing usage of transfusion and blood products in the DIC therapy.
